Acute liver failure in a pediatric patient with congenital dyserythropoietic anemia type I treated with deferasirox

Acute liver failure in a pediatric patient with congenital dyserythropoietic anemia type I treated with deferasirox

Congenital dyserythropoietic anemias (CDA) represent a heterogeneous group of disorders characterized by morphological abnormalities of erythroid precursor cells and various degrees of hemolysis. Iron overload is a result of continuous hemolysis and recurrent transfusions. It is treated with iron ch...

Full description

Bibliographic Details
Main Authors:	Galina Ling, Vered Pinsk, Inbal Golan-Tripto, Eduard Ling
Format:	Article
Language:	English
Published:	MDPI AG 2015-09-01
Series:	Hematology Reports
Subjects:	Congenital dyserythropoietic anemia deferasirox acute liver failure N-acetylcysteine
Online Access:	http://www.pagepress.org/journals/index.php/hr/article/view/5987

Similar Items

Rare congenital Dyserythropoietic anemia of childhood: A case report
by: Hamzeh F. Al Hussien, et al.
Published: (2023-02-01)

Congenital dyserythropoietic anemia type IV with kruppel-like factor 1 E325K mutation in a preterm neonate: Case and literature review
by: Reema Garegrat, et al.
Published: (2022-01-01)

Congenital dyserythropoietic anemia in children: Case series with review of literature
by: Jasmita Dass, et al.
Published: (2024-06-01)

Diagnosis: Congenital Dyserythropoietic Anemia Type 2 Due to Compound Heterozygote Mutation in SEC23B Gene
by: Fatih Demircioğlu, et al.
Published: (2015-07-01)

Development of High-Resolution Melting Curve Analysis for rapid detection of SEC23B gene mutation causing Congenital Dyserythropoietic Anemia type II in Indian population
by: Arati Nandan Saptarshi, et al.
Published: (2023-07-01)

New Cases and Mutations in <i>SEC23B</i> Gene Causing Congenital Dyserythropoietic Anemia Type II
by: Melina Mara Musri, et al.
Published: (2023-06-01)

RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway
by: Gianluca De Rosa, et al.
Published: (2020-08-01)

Characterization of the interactions between Codanin-1 and C15Orf41, two proteins implicated in congenital dyserythropoietic anemia type I disease
by: Grace Swickley, et al.
Published: (2020-03-01)

Novel PKLR missense mutation (A300P) causing pyruvate kinase deficiency in an Omani Kindred—PK deficiency masquerading as congenital dyserythropoietic anemia
by: Naglaa Fawaz, et al.
Published: (2022-02-01)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018-05-01)

Severe Presentation of Congenital Hemolytic Anemias in the Neonatal Age: Diagnostic and Therapeutic Issues
by: Valeria Cortesi, et al.
Published: (2021-08-01)

Modelling the erythroblastic island niche of dyserythropoietic anaemia type IV patients using induced pluripotent stem cells
by: Alisha May, et al.
Published: (2023-04-01)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
by: Laura Galeotti, et al.
Published: (2021-08-01)

Desensibilización a deferasirox en una paciente con hemocromatosis. Reporte de un caso
by: Nadia Karina Aguilar Hinojosa, et al.
Published: (2023-08-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Handan Duman, et al.
Published: (2014-08-01)

Ablation of <i>Tmcc2</i> Gene Impairs Erythropoiesis in Mice
by: Ranju Kumari, et al.
Published: (2022-05-01)

In vitro Studying of Deferasirox Side effects on the Structure and the Function of Bovine Liver Catalase
by: Maryam Moradi, et al.
Published: (2014-11-01)

In vitro Studying of Deferasirox Side effects on the Structure and the Function of Bovine Liver Catalase
by: Maryam Moradi, et al.
Published: (2014-11-01)

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
by: Alba Rodríguez-García, et al.
Published: (2019-10-01)

Pengaruh Deferasirox Terhadap Kadar T4 dan TSH Pada B-Thalassemia Mayor dengan Kadar Ferritin Tinggi
by: Dewi Ratih P, et al.
Published: (2016-11-01)

Synthesis and Characterization of Deferasirox PLGA Nanoparticles and Investigation of Toxicity in Cell Model
by: Hamidreza Mohammadi, et al.
Published: (2022-11-01)

Deferasirox Nanosuspension Loaded Dissolving Microneedles for Intradermal Delivery
by: Hafsa Shahid Faizi, et al.
Published: (2022-12-01)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
by: Hana Votavova, et al.
Published: (2021-01-01)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
by: Alkistis Adramerina, et al.
Published: (2022-02-01)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
by: Ricchi P, et al.
Published: (2015-12-01)

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias
by: Ali T. Taher, et al.
Published: (2018-11-01)

Hidrops fetal no inmune por anemia diseritropoyética congénita
by: Laura Blasco G, et al.
Published: (2011-01-01)

SEC23B Loss-of-Function Suppresses Hepcidin Expression by Impairing Glycosylation Pathway in Human Hepatic Cells
by: Barbara Eleni Rosato, et al.
Published: (2022-01-01)

Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review
by: Martin Scoglio, et al.
Published: (2021-12-01)

A Deferasirox Derivative That Acts as a Multifaceted Platform for the Detection and Quantification of Fe<sup>3+</sup>
by: Axel Steinbrueck, et al.
Published: (2021-03-01)

Renal function in patients with thalassemia major receiving Exjade® dispersible tablets and a new film-coated tablet formulation of deferasirox (Nanojade®)
by: Vahid Falahati, et al.
Published: (2022-01-01)

Juvenile Hemochromatosis: Rheumatic Manifestations of 2 Sisters Responding to Deferasirox Treatment. A Case Series and Literature Review
by: Alqanatish J, et al.
Published: (2021-01-01)

Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1
by: Bourafai-Aziez A, et al.
Published: (2021-12-01)

Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A
by: Kosei Ishimaru, et al.
Published: (2024-01-01)

Comparison of the Mean Serum Ferritin Levels in Thalassaemia Major Patients after Giving Deferasirox and Deferoxamine
by: Seema Aftab, et al.
Published: (2017-12-01)

Comparison of deferasirox and deferoxamine effect on liver enzyme activities and ferritin level in patients with beta-thalassemia
by: Rasul Jameel Ali, et al.
Published: (2020-12-01)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
by: Trisha E. Wong, et al.
Published: (2021-09-01)

Congenital dyserythropoietic anemias
by: Renella, R, et al.
Published: (2011)

M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer
by: Yongmei Zhao, et al.
Published: (2021-09-01)

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions
by: Chalmers AW, et al.
Published: (2016-02-01)